Beow Yong Yeap, ScD

Massachusetts General Hospital

Massachusetts General Hospital


byeap@partners.org

Massachusetts General Hospital


byeap@partners.org

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Beow Yong Yeap, ScD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Beow Yong Yeap, ScD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Assistant Biostatistician, MGH Cancer Center, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My primary interests lie in novel and creative applications of biostatistics to translational and clinical areas of oncology. While I have extensive expertise and experience in the design and analysis of cancer clinical trials, I have a increasing interest in translational research. My translational efforts are focused on the DF/HCC SPORE in Lung Cancer and the multi-disciplinary program in the etiology, pathobiology and therapy of mesothelioma based at BWH. I also work with DF/HCC investigators on specific projects in thoracic cancers and, more recently, in gastrointestinal malignancies. In addition to serving as the clinical trails statistician for the Program Project in Proton Radiation Therapy Research, my research at the MGH Cancer Center includes molecular epidemiology of esophageal cancer as well as clincal and translational collaborations in bone marrow transplantation.

Publications

Powered by Harvard Catalyst
  • Grassberger C, Shinnick D, Yeap BY, Tracy M, Ellsworth S, Hess CB, Weyman EA, Gallotto SL, Lawell MP, Bajaj B, Ebb DH, Ioakeim-Ioannidou M, Loeffler J, MacDonald S, Tarbell NJ, Yock TI. Circulating Lymphocyte Counts Early During Radiotherapy are Associated with Recurrence in Pediatric Medulloblastoma. Int J Radiat Oncol Biol Phys 2021. PubMed
  • De Rienzo A, Chirieac LR, Hung YP, Severson DT, Freyaldenhoven S, Gustafson CE, Dao NT, Meyerovitz CV, Oster ME, Jensen RV, Yeap BY, Bueno R, Richards WG. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol 2020. PubMed
  • Patteson BE, Baliga S, Bajaj BVM, MacDonald SM, Yeap BY, Gallotto SL, Giblin MJ, Weyman EA, Ebb DH, Huang MS, Jones RM, Tarbell NJ, Yock TI. Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. 2020. PubMed
  • Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist 2020. PubMed
  • Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY, Chin E, Do A, Marble HD, Stevens SE, Digumarthy SR, Saxena A, Nagy RJ, Benes CH, Azzoli CG, Lawrence MS, Gainor JF, Shaw AT, Hata AN. MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res 2020. PubMed
  • Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ignatius Ou SH, Riely GJ, Shaw AT. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. J Thorac Oncol 2019. PubMed
  • Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. 2019; 9:1372-1387. PubMed
  • Jimenez RB, Hickey S, DePauw N, Yeap BY, Batin E, Gadd MA, Specht M, Isakoff SJ, Smith BL, Liao EC, Colwell AS, Ho A, Januzzi JL, Passeri J, Neilan TG, Taghian AG, Lu HM, MacDonald SM. Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation. J Clin Oncol 2019. PubMed
  • Wo JY, Plastaras JP, Metz JM, Jiang W, Yeap BY, Drapek LC, Adams J, Baglini C, Ryan DP, Murphy JE, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, DeLaney TF, Ben-Josef E, Hong TS. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys 2019. PubMed
  • Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer. Clin Cancer Res 2018. PubMed
  • Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 2018; 6:75. PubMed
  • Schapira E, Hubbeling H, Yeap BY, Mehan WA, Shaw AT, Oh K, Gainor JF, Shih HA. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 2018; 101:624-629. PubMed
  • Burgess L, Pulsifer MB, Grieco JA, Weinstein ER, Gallotto S, Weyman E, MacDonald SM, Tarbell NJ, Yeap BY, Yock TI. Estimated IQ Systematically Underestimates Neurocognitive Sequelae in Irradiated Pediatric Brain Tumor Survivors. Int J Radiat Oncol Biol Phys 2018; 101:541-549. PubMed
  • Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ignatius Ou SH, Shaw AT, Riely GJ. Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. J Thorac Oncol 2018. PubMed
  • Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018. PubMed
  • Lalani N, Winkfield KM, Soto DE, Yeap BY, Ng AK, Mauch PM, Jimenez RB. Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience. Breast Cancer Res Treat 2018; 169:197-202. PubMed
  • Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 2018. PubMed
  • Gill RR, Yeap BY, Bueno R, Richards WG. Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. Journal of the National Cancer Institute 2018; 110:258-264. PubMed
  • Gentile MS, Yeap BY, Paganetti H, Goebel CP, Gaudet DE, Gallotto SL, Weyman EA, Morgan ML, MacDonald SM, Giantsoudi D, Adams J, Tarbell NJ, Kooy H, Yock TI. Brainstem Injury in Pediatric Patients With Posterior Fossa Tumors Treated With Proton Beam Therapy and Associated Dosimetric Factors. Int J Radiat Oncol Biol Phys 2018; 100:719-729. PubMed
  • Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol 2018. PubMed
  • Hess CB, Indelicato DJ, Paulino AC, Hartsell WF, Hill-Kayser CE, Perkins SM, Mahajan A, Laack NN, Ermoian RP, Chang AL, Wolden SL, Mangona VS, Kwok Y, Breneman JC, Perentesis JP, Gallotto SL, Weyman EA, Bajaj BVM, Lawell MP, Yeap BY, Yock TI. An Update From the Pediatric Proton Consortium Registry. 2018; 8:165. PubMed
  • Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute 2017. PubMed
  • Sanford NN, Yeap BY, Larvie M, Daartz J, Munzenrider JE, Liebsch NJ, Fullerton B, Pan E, Loeffler JS, Shih HA. Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas. Int J Radiat Oncol Biol Phys 2017. PubMed
  • Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol 2018. PubMed
  • De Rienzo A, Cook RW, Wilkinson J, Gustafson CE, Amin W, Johnson CE, Oelschlager KM, Maetzold DJ, Stone JF, Feldman MD, Becich MJ, Yeap BY, Richards WG, Bueno R. Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues. J Mol Diagn 2016; 19:65-71. PubMed
  • Burgess L, Pulsifer M, Yeap BY, Grieco J, Weinstein ER, MacDonald S, Tarbell NJ, Yock TI. Estimated IQ (EIQ) Systematically Overestimates Full-Scale IQ (FSIQ) in Survivors Irradiated for Pediatric Brain Tumors. Int J Radiat Oncol Biol Phys 2016; 96:S232. PubMed
  • Patel SA, Aizer AA, Weyman E, Lu HM, Yeap BY, Busse PM, Chan AW. Multimodal Assessment of Hearing Function After Chemoradiation for Nasopharyngeal Carcinoma: A Prospective Study. Int J Radiat Oncol Biol Phys 2016; 96:E338. PubMed
  • DeLaney TF, Chen YL, Adams JA, Hickey S, Wang D, Baldini EH, Bernstein K, Yeap BY, Hahn SM, Nielsen GP, Choy E, Mullen JT, Yoon SS. Phase 1 Trial of Preoperative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas. Int J Radiat Oncol Biol Phys 2016; 96:S23. PubMed
  • Dyer MA, McDonnell EI, Yeap BY, Depauw N, Wolfgang JA, Wo JY, DeLaney TF, Ben-Josef E, Crane CH, Zhu AX, Hong TI. Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2016; 96:E174-E175. PubMed
  • Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz K, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis. Clin Cancer Res 2016. PubMed
  • Giantsoudi D, Sethi RV, Yeap BY, Eaton BR, Ebb DH, Caruso PA, Rapalino O, Chen YL, Adams JA, Yock TI, Tarbell NJ, Paganetti H, MacDonald SM. Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. Int J Radiat Oncol Biol Phys 2016; 95:287-96. PubMed
  • Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, Jones RM, MacDonald SM, Pulsifer MB, Lavally B, Abrams AN, Huang MS, Marcus KJ, Tarbell NJ. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016; 17:287-98. PubMed
  • Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2015. PubMed
  • De Rienzo A, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, Zheng Y, Holman AG, Wang YE, Dal Cin P, Fletcher JA, Rubio R, Croft L, Quackenbush J, Sugarbaker PE, Munir KJ, Battilana JR, Gustafson C, Chirieac LR, Ching SM, Wong J, Tay LC, Rudd S, Hercus R, Sugarbaker DJ, Richards WG, Bueno R. Gender-Specific Molecular and Clinical Features underlie Malignant Pleural Mesothelioma. Cancer Res 2015. PubMed
  • Sherman JC, Colvin MK, Mancuso SM, Batchelor TT, Oh KS, Loeffler JS, Yeap BY, Shih HA. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J. Neurooncol. 2015. PubMed
  • Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res 2015. PubMed
  • Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, Winrich BK, Batchelor TT, Thornton LT, Mancuso SM, Saums MK, Oh KS, Curry WT, Loeffler JS, Yeap BY. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer 2015. PubMed
  • Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res 2015. PubMed
  • Mullen JT, Hornicek FJ, Harmon DC, Raskin KA, Chen YL, Szymonifka J, Yeap BY, Choy E, DeLaney TF, Nielsen GP. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer 2014. PubMed
  • Mouw KW, Sethi RV, Yeap BY, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Munzenrider JE, Adams J, Grabowski E, Mukai S, Shih HA. Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Yock TI, Bhat S, Szymonifka J, Yeap BY, Delahaye J, Donaldson SS, MacDonald SM, Pulsifer MB, Hill KS, DeLaney TF, Ebb D, Huang M, Tarbell NJ, Fisher PG, Kuhlthau KA. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol 2014. PubMed
  • Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer 2014; 85:239-44. PubMed
  • DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, Depauw N, Nielsen GP, Harmon DC, Yoon SS, Chen YL, Schwab JH, Hornicek FJ. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 2014. PubMed
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20:730-4. PubMed
  • De Rienzo A, Yeap BY, Cibas ES, Richards WG, Dong L, Gill RR, Sugarbaker DJ, Bueno R. Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies. J Mol Diagn 2014; 16:267-72. PubMed
  • Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo C, Yock TI, Tarbell NJ, Marcus KJ, Mukai S, MacDonald SM. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 2013; 120:126-33. PubMed
  • Chirieac LR, Barletta JA, Yeap BY, Richards WG, Tilleman T, Bueno R, Baldini EH, Godleski J, Sugarbaker DJ. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol 2013; 31:4544-9. PubMed
  • Burt BM, Ali SO, DaSilva MC, Yeap BY, Richards WG, Baldini EH, Sugarbaker DJ. Clinical indications and results after chest wall resection for recurrent mesothelioma. J Thorac Cardiovasc Surg 2013; 146:1373-9; discussion 1379-80. PubMed
  • Macdonald SM, Sethi R, Lavally B, Yeap BY, Marcus KJ, Caruso P, Pulsifer M, Huang M, Ebb D, Tarbell NJ, Yock TI. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. 2013; 15:1552-9. PubMed
  • Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013; 19:4532-40. PubMed
  • Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19:4273-81. PubMed
  • MacDonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, Smith BL, Yeap BY, Adams J, Delaney TF, Kooy H, Lu HM, Taghian AG. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 2013; 119:1729-35. PubMed
  • De Amorim Bernstein K, Sethi R, Trofimov A, Zeng C, Fullerton B, Yeap BY, Ebb D, Tarbell NJ, Yock TI, MacDonald SM. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys 2013; 86:114-20. PubMed
  • De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, Wang YE, Quackenbush J, Jensen RV, Bueno R. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res 2013. PubMed
  • Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, Richards WG. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013; 145:955-63. PubMed
  • Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 2013; 20:1365-73. PubMed
  • Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer 2013; 79:193-7. PubMed
  • Look Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, Nielsen GP, Szymonifka J, Yeap BY, DeLaney TF, Mullen JT. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer 2013. PubMed
  • Onozato ML, Kovach AE, Yeap BY, Morales-Oyarvide V, Klepeis VE, Tammireddy S, Heist RS, Mark EJ, Dias-Santagata D, Iafrate AJ, Yagi Y, Mino-Kenudson M. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol 2013. PubMed
  • Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, Chen YL, DeLaney TF, Nielsen GP, Mullen JT. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol 2012. PubMed
  • Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, Choy E, Yoon SS, Raskin KA, Hornicek FJ, Nielsen GP. β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013; 18:1043-9. PubMed
  • Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, Rosenberg AE, Harmon DC, Choy E, Yoon SS, Raskin KA, Petur Nielsen G, Hornicek FJ. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012. PubMed
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012; 7:1767-74. PubMed
  • Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ, Mino-Kenudson M. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012; 25:1462-72. PubMed
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012; 18:4406-14. PubMed
  • Kuhlthau KA, Pulsifer MB, Yeap BY, Rivera Morales D, Delahaye J, Hill KS, Ebb D, Abrams AN, Macdonald SM, Tarbell NJ, Yock TI. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol 2012; 30:2079-86. PubMed
  • Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, Liebsch NJ, Tarbell NJ, Yock TI. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012. PubMed
  • Wang H, Yang Y, Wang G, Wang S, Yeap BY, Sykes M, Yang YG. Donor bone marrow-derived T cells inhibit GVHD induced by donor lymphocyte infusion in established mixed allogeneic hematopoietic chimeras. PLoS ONE 2012; 7:e47120. PubMed
  • De Rienzo A, Dong L, Yeap BY, Jensen RV, Richards WG, Gordon GJ, Sugarbaker DJ, Bueno R. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2011; 17:310-6. PubMed
  • Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, Delaney TF, Fernandez-Del Castillo C. Phase I Study of Preoperative Short-Course Chemoradiation with Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head. Int J Radiat Oncol Biol Phys 2010; 79:151-7. PubMed
  • Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16:5873-82. PubMed
  • Lutton BV, Cho PS, Hirsh EL, Ferguson KK, Teague AG, Hanekamp JS, Chi N, Goldman SN, Messina DJ, Houser S, Yeap BY, Popma SH, Sachs DH, Huang CA. Approaches to avoid immune responses induced by repeated subcutaneous injections of allogeneic umbilical cord tissue-derived cells. Transplantation 2011; 90:494-501. PubMed
  • Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010; 195:W221-8. PubMed
  • Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010; 34:1193-8. PubMed
  • Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, Ho V, Alyea EP, Soiffer RJ, Spitzer TR, Antin JH. Donor Derived Second Hematologic Malignancies after Cord Blood Transplantation. Biol Blood Marrow Transplant 2010; 16:1025-31. PubMed
  • Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis. Am J Pathol 2010; 177:415-23. PubMed
  • Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010; 5:1048-53. PubMed
  • Duran-Struuck R, Cho PS, Teague AG, Fishman B, Fishman AS, Hanekamp JS, Moran SG, Wikiel KJ, Ferguson KK, Lo DP, Duggan M, Arn JS, Billiter B, Horner B, Houser S, Yeap BY, Westmoreland SV, Spitzer TR, McMorrow IM, Sachs DH, Bronson RT, Huang CA. Myelogenous leukemia in adult inbred MHC-defined miniature swine: A model for human myeloid leukemias. 2010; 135:243-56. PubMed
  • Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010; 133:922-34. PubMed
  • Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 2010; 139:1233-40. PubMed
  • Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L, Mujoomdar A, Jaklitsch MT, Bueno R, Sugarbaker DJ. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 2010; 116:1510-7. PubMed
  • Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010; 116:659-69. PubMed
  • Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88. PubMed
  • Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009; 106:19503-8. PubMed
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009; 69:8341-8. PubMed
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009; 69:8341-8348.
  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin Oncol 2009; 27:4247-53. PubMed
  • Pirl WF, Greer J, Temel JS, Yeap BY, Gilman SE. Major Depressive Disorder in Long-Term Cancer Survivors: Analysis of the National Comorbidity Survey Replication. J Clin Oncol 2009; 27:4130-4. PubMed
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15:5267-73. PubMed
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216-23. PubMed
  • Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 2009; 115:3640-50. PubMed
  • Barletta JA,Perner S,Iafrate AJ,Yeap BY,Weir BA,Johnson LA,Johnson BE,Meyerson M,Rubin MA,Travis WD,Loda M,Chirieac LR. Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma. J Cell Mol Med 2010; 13:1977-86. PubMed
  • Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138:405-11. PubMed
  • DeLaney TF,Liebsch NJ,Pedlow FX,Adams J,Dean S,Yeap BY,McManus P,Rosenberg AE,Nielsen GP,Harmon DC,Spiro IJ,Raskin KA,Suit HD,Yoon SS,Hornicek FJ. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2008; 74:732-9. PubMed
  • Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15:3484-94. PubMed
  • Gordon GJ,Dong L,Yeap BY,Richards WG,Glickman JN,Edenfield H,Mani M,Colquitt R,Maulik G,Van Oss B,Sugarbaker DJ,Bueno R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. Journal of the National Cancer Institute 2009; 101:678-86. PubMed
  • Delaney M,Cutler CS,Haspel RL,Yeap BY,McAfee SL,Dey BR,Attar E,Kao G,Alyea EP,Koreth J,Ho VT,Saidman S,Liney D,Sese D,Soiffer RJ,Spitzer TR,Antin JH,Ballen KK. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion 2009; 49:995-1002. PubMed
  • Kuang Y,Rogers A,Yeap BY,Wang L,Makrigiorgos M,Vetrand K,Thiede S,Distel RJ,Janne PA. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009; 15:2630-6. PubMed
  • Wang H,Asavaroengchai W,Yeap BY,Wang MG,Wang S,Sykes M,Yang YG. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood 2009; 113:3612-9. PubMed
  • Winkfield KM,Linsenmeier C,Yock TI,Grant PE,Yeap BY,Butler WE,Tarbell NJ. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int J Radiat Oncol Biol Phys 2008; 73:716-21. PubMed
  • Yusuf RZ, Dey B, Yeap BY, McAfee S, Attar E, Sepe PS, Dube C, Spitzer TR, Ballen KK. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43:37-42. PubMed
  • Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14:7060-7. PubMed
  • Saad AG,Yeap BY,Thunnissen FB,Pinkus GS,Pinkus JL,Loda M,Sugarbaker DJ,Johnson BE,Chirieac LR. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 2008; 113:2129-38. PubMed
  • Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008; 99:245-52. PubMed
  • Macdonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T. Proton Radiotherapy for Childhood Ependymoma: Initial Clinical Outcomes and Dose Comparisons. Int J Radiat Oncol Biol Phys 2008; 71:979-86. PubMed
  • Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008; 8:129-38. PubMed
  • Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61:549-58. PubMed
  • Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, Ho VT, Koreth J, Dey BR, McAfee SL, Attar EC, Spitzer T, Antin JH, Ballen KK. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant 2008; 41:523-9. PubMed
  • Allen AM, Mentzer SJ, Yeap BY, Soto R, Baldini EH, Rabin MS, Sugarbaker DJ, Bueno R. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 2008; 112:1106-13. PubMed
  • Kerber RA,Amos CI,Yeap BY,Finkelstein DM,Thomas DC. Design considerations in a sib-pair study of linkage for susceptibility loci in cancer. BMC Med Genet 2008; 9:64. PubMed
  • Richards W, Van Oss S, Glickman J, Chirieac L, Yeap B, Dong L, Gordon G, Mercer H, Gill K, Imrich A, Bueno R, Sugarbaker D. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem 2007. PubMed
  • Jänne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007; 25:3936-44. PubMed
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13:838-43. PubMed
  • Liu G, Zhou W, Yeap BY, Su L, Wain JC, Poneros JM, Nishioka NS, Lynch TJ, Christiani DC. XRCC1 and XPD Polymorphisms and Esophageal Adenocarcinoma Risk. Carcinogenesis 2007; 28:1254-8. PubMed
  • Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007; 211:447-54. PubMed
  • Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 2007; 211:439-46. PubMed
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-6. PubMed
  • Linden PA, Yeap BY, Chang MY, Henderson WG, Jaklitsch MT, Khuri S, Sugarbaker DJ, Bueno R. Morbidity of lung resection after prior lobectomy: results from the Veterans Affairs National Surgical Quality Improvement Program. Ann Thorac Surg 2007; 83:425-31; discussion 432. PubMed
  • Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13:82-9. PubMed
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer. J Clin Invest 2006; 116:2695-706. PubMed
  • Gordon GJ, Deters LA, Nitz MD, Lieberman BC, Yeap BY, Bueno R. Differential diagnosis of solitary lung nodules with gene expression ratios. J Thorac Cardiovasc Surg 2006; 132:621-7. PubMed
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-14. PubMed
  • Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24:1561-7. PubMed
  • Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT, Sugarbaker DJ, Bueno R. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131:438-46. PubMed
  • Mouw KW, Yeap BY, Caruso P, Fay A, Misra M, Sethi RV, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Freitag SK, Munzenrider JE, Grabowski E, Katz M, Kuhlthau K, DeCastro D, Heidary G, Ciralsky J, Mukai S, Shih HA. Analysis of patient outcomes following proton radiation therapy for retinoblastoma. Adv Radiat Oncol 2017; 2:44-52. PubMed
  • Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. 2014; 4:316-22. PubMed
  • DeLaney TF, Chen YL, Baldini EH, Wang D, Adams J, Hickey SB, Yeap BY, Hahn SM, De Amorim Bernstein K, Nielsen GP, Choy E, Mullen JT, Yoon SS. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol 2017; 2:85-93. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Beow Yong Yeap, ScD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members